We found that PYK2 inhibition abolished the ability of VLA-4/VCAM-1 interaction to induce doxorubicin efflux and resistance indicating that PYK2 plays a major role in VLA-4-induced T-ALL chemoresistance. The gene discussed is PTK2B; the disease is acute lymphoblastic leukemia.